LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway

LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway

Internal tandem duplications (ITD) mutation within FMS-like tyrosine kinase 3 (FLT3), the most frequent mutation happens in almost 20% acute myeloid leukemia (AML) patients, always predicts a poor prognosis. As a small molecule tyrosine kinase inhibitor, sorafenib is clinically used for the treatmen...

Full description

Bibliographic Details
Main Authors: Amin Huang, Peiting Zeng, Yinguang Li, Wenhua Lu, Yaoming Lai
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Oncology
Subjects:
FMS-like tyrosine kinase 3
Internal tandem duplication
LY294002
Drug resistance
Acute myeloid leukemia
PI3K/Akt
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.782065/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.782065/full

Similar Items